Navigation Links
Aeolus Pharmaceuticals Announces Successful Completion of Multiple,Dose Safety Study of AEOL 10150

LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Mar 22, 2007 - Aeolus Pharmaceuticals, Inc. (OTCBB:AOLS) announced today the successful completion of the analysis of results from the Company's phase 1 multiple-dose study of AEOL 10150 ("Study 102"). The clinical direction for AEOL 10150 is currently under consideration, with the most likely targets for an efficacy study as a protector of healthy cells in radiation therapy in lung cancer and/or head and neck cancer and Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's disease").

Study 102 was a double-blind, randomized, placebo-controlled Phase 1 clinical study to assess the safety, tolerability, and pharmacokinetic profile of three doses of AEOL 10150 administered by subcutaneous ("SC") injection or infusion in patients with ALS. Three groups of six subjects (four receiving drug, two placebo, and total 18 subjects) were studied. Each subject in the first two cohorts received bid SC injections of AEOL 10150 or placebo for six days followed by a single SC injection on the seventh day for a total of 13 injections. In the first cohort, each injection was 40 mg and in the second cohort each injection was 60 mg.

There were two dosing modifications in the third cohort. First, the dosage was changed from a total fixed daily dose to a weight dependent dose (i.e. mg/kg) to ensure that each subject received the same dose irrespective of weight. Second, the method of subcutaneous compound delivery was changed from subcutaneous administration via needle and syringe to continuous subcutaneous delivery via infusion cannula. Subjects in the third cohort received a daily dose of 2 mg/kg delivered by osmotic infusion pump over 24 hours for 6.5 days.

The safety results can be summarized as follows: All subjects completed the study. There were no serious or clinically significant adverse events. Mild decreases in sitting systolic and diastolic blood pressure were more fr
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Study Demonstrating Aeolus Compounds Neuroprotection in Parkinsons Disease Published in the Journal of Neuroscience
2. Aeolus Pharmaceuticals AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation
3. Aeolus Pharmaceuticals AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy
4. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
(Date:7/3/2015)... July 3, 2015 A global ... hypertension, diabetes and thyroid disorders in Latin ... a major conference dedicated to these diseases. ... Online , Manage Hypertension Online and ... by EXCEMED - combine the world,s top ...
(Date:7/3/2015)... , July 3, 2015 Redwood ... Broda Technologies Co., Ltd., operating in both the US ... company,s proprietary IntelliGel ® supramolecular hydrogel technology in ... and other ophthalmic therapies. The Broda technology offers many ... is a free-forming liquid and with low concentrations of ...
(Date:7/2/2015)... N.C. , July 2, 2015 ... employees to capture critical product and market insights ... many benefits to employee-based studies, it is essential ... their own internal employees to capture critical business-related ... by benchmarking firm, Best Practices, LLC, most benchmarked ...
Breaking Medicine Technology:Combating Three Major Chronic Diseases in Latin America With Medical Education 2Redwood Pharma Licenses Novel Hydrogel Drug Delivery Technology From Broda Technologies 2Leveraging Employee Insights to Produce Cutting-Edge Market Research 2
... Physics Consulting, the leading national provider of medical and health physics ... an exclusive arrangement with Digirad Corporation to provide all radiation safety ... division, Digirad Imaging Solutions, Inc. (DIS). , ... "West Physics prides itself on being the ...
... INDIANAPOLIS , May 21 Despite ... of homelessness, Joseph Rogers refused to let ... potential imprint on the world. Despite once being branded ... challenges of being a change agent in mental health ...
Cached Medicine Technology:West Physics Consulting Signs Exclusive Arrangement With Digirad Corporation 2West Physics Consulting Signs Exclusive Arrangement With Digirad Corporation 3West Physics Consulting Signs Exclusive Arrangement With Digirad Corporation 4Annual Welcome Back Awards Program Honors Individuals for Tremendous Contributions to the Depression Community 2Annual Welcome Back Awards Program Honors Individuals for Tremendous Contributions to the Depression Community 3Annual Welcome Back Awards Program Honors Individuals for Tremendous Contributions to the Depression Community 4Annual Welcome Back Awards Program Honors Individuals for Tremendous Contributions to the Depression Community 5Annual Welcome Back Awards Program Honors Individuals for Tremendous Contributions to the Depression Community 6Annual Welcome Back Awards Program Honors Individuals for Tremendous Contributions to the Depression Community 7
(Date:7/4/2015)... , ... July 04, 2015 , ... ... Surgeons published the results of an annual member survey , detailing the ... States. More recently, the group broke that raw data down into charts detailing ...
(Date:7/3/2015)... ... July 03, 2015 , ... Brendon Burchard's new ... a buzz of media attention. In an effort to spread the news, a ... , "These days many people are feeling overwhelmed by stress and fatigue," reports ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. E. Smith, the ... to lead a national president recruitment for Regional Care, Inc. in ... B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/3/2015)... ... ... Jennifer Renee Hanes, DO is the new Medical Director of its Sienna ... freestanding emergency rooms in the United States. , “We are excited to welcome Dr. ... Medical Director of First Choice Emergency Room, Dr. James M. Muzzarelli. , Dr. ...
(Date:7/3/2015)... ... July 03, 2015 , ... The Celebrity Dresses is currently running a promotion ... of celebrities will have the opportunity to get 10% discount on orders that are ... do not have to use coupon codes or remember redemption codes. , There ...
Breaking Medicine News(10 mins):Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 2Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 3Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3Health News:Celebrity Fashion Summer Party Dresses on sale at TheCelebrityDresses.com 2
... and damage claims relating to Chinese drywall is the ... New Orleans. The event will be co-chaired by ... HB Litigation Conferences LLC, host of the event.HB also ... attorneys and in-house counsel, the other for litigators interested ...
... Reflect Recommendations from American Association for Homecare Anti-Fraud ... Association for Homecare applauds Senators Mel Martinez (R-Fla.), ... the "STOP" Act (S. 975) which targets Medicare ... Taxpayers Obligation Protection (STOP) Act is designed to ...
... BELLUS Health Inc. ("BELLUS Health" or the "Company") (TSX: ... 31, 2009. The Company reported a net loss of ... $13,042,000 ($0.27 per share) for the same period the ... mainly due to a reduction in research and development ...
... to surgery, anesthesia, experts note, , , WEDNESDAY, May 6 ... with Alzheimer,s who are hospitalized might accelerate their cognitive ... people with Alzheimer,s who had an episode of delirium ... decline that was three times faster than that of ...
... Reporting online in the American Journal of Pathology ... have implicated the loss of a stromal protein called ... with breast cancer, predicting early disease recurrence, metastasis and ... in the stroma also appeared to be a marker ...
... Two scientists whose work has led to new ... dystrophy have been chosen to receive the 2009 March ... and Louis M. Kunkel, Ph.D., share the 2009 March ... genes and proteins that cause muscular dystrophy, a disorder ...
Cached Medicine News:Health News:HB Litigation Conferences Announces Conference and Two Teleconferences on Chinese Drywall Litigation and Insurance 2Health News:American Association for Homecare Applauds Senate 'STOP' Act, Which Aims to Prevent Medicare Fraud and Abuse 2Health News:American Association for Homecare Applauds Senate 'STOP' Act, Which Aims to Prevent Medicare Fraud and Abuse 3Health News:American Association for Homecare Applauds Senate 'STOP' Act, Which Aims to Prevent Medicare Fraud and Abuse 4Health News:American Association for Homecare Applauds Senate 'STOP' Act, Which Aims to Prevent Medicare Fraud and Abuse 5Health News:BELLUS Health reports results for first quarter of fiscal 2009 2Health News:BELLUS Health reports results for first quarter of fiscal 2009 3Health News:BELLUS Health reports results for first quarter of fiscal 2009 4Health News:BELLUS Health reports results for first quarter of fiscal 2009 5Health News:BELLUS Health reports results for first quarter of fiscal 2009 6Health News:BELLUS Health reports results for first quarter of fiscal 2009 7Health News:BELLUS Health reports results for first quarter of fiscal 2009 8Health News:BELLUS Health reports results for first quarter of fiscal 2009 9Health News:BELLUS Health reports results for first quarter of fiscal 2009 10Health News:BELLUS Health reports results for first quarter of fiscal 2009 11Health News:BELLUS Health reports results for first quarter of fiscal 2009 12Health News:BELLUS Health reports results for first quarter of fiscal 2009 13Health News:BELLUS Health reports results for first quarter of fiscal 2009 14Health News:BELLUS Health reports results for first quarter of fiscal 2009 15Health News:BELLUS Health reports results for first quarter of fiscal 2009 16Health News:BELLUS Health reports results for first quarter of fiscal 2009 17Health News:BELLUS Health reports results for first quarter of fiscal 2009 18Health News:BELLUS Health reports results for first quarter of fiscal 2009 19Health News:BELLUS Health reports results for first quarter of fiscal 2009 20Health News:BELLUS Health reports results for first quarter of fiscal 2009 21Health News:BELLUS Health reports results for first quarter of fiscal 2009 22Health News:BELLUS Health reports results for first quarter of fiscal 2009 23Health News:BELLUS Health reports results for first quarter of fiscal 2009 24Health News:Delirium Episodes Could Hasten Alzheimer's-Linked Decline 2Health News:Delirium Episodes Could Hasten Alzheimer's-Linked Decline 3Health News:New universal breast cancer marker predicts recurrence and clinical outcome 2Health News:New universal breast cancer marker predicts recurrence and clinical outcome 3Health News:March of Dimes Awards $250,000 Prize to Scientists Unraveling the Causes of Muscular Dystrophy 2
LabPak II is a comprehensive multi-user Laboratory Information System designed to meet the requirements of the larger POL, small hospital or private laboratory. It is the next step up from the LabPak...
... The Bohn™ Extremity ... - this single extremity ... antimicrobial impregnated "Vi-Drapes" ...the ... current "extremity drape". A ...
... Hip Pouch Drape is designed as an add-on to ... the lower extremity into a sterile pouch during total ... and is a generous 60 inches long and 27 ... with a 4 inch wide adhesive strip that runs ...
... Packs ,3M offers a line of packs ... Impervious material to create a sterile field ... Drape Sheets, Split Sheets and covers for ... The 9012 LA contains a larger anesthesia ...
Medicine Products: